Glucosamine sulphate: an umbrella review of health outcomes

Veronese, N.; Demurtas, J.; Smith, L.; Reginster, Jean-Yves; Bruyère, Olivier; Beaudart, Charlotte; Honvo, Germain; Maggi, S

doi:10.1177/1759720X20975927

Download

Article (Scientific journals)

Glucosamine sulphate: an umbrella review of health outcomes

Veronese, N.; Demurtas, J.; Smith, L. et al.

2020 • In Therapeutic Advances in Musculoskeletal Disease, 12, p. 1-12

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/257702

DOI
10.1177/1759720X20975927

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Glucosamine sulphate - an umbrella review of health outcomes.pdf

Publisher postprint (335.61 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Glucosamine Sulphate; osteoarthritis; umbrella review

Abstract :

[en] Background and Aims: Glucosamine sulphate (GS) can be used as background therapy in people affected by knee osteoarthritis (OA). Knowledge regarding the efficacy and safety of GS is of importance since its use worldwide is increasing. Therefore, the present study aimed to map and grade the diverse health outcomes associated with GS using an umbrella review approach. Methods: Medline, Cinahl and Embase databases were searched until 1 April 2020. An umbrella review of systematic reviews and meta-analyses of randomized controlled trials (RCTs) was carried out. The evidence from the RCTs was graded using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) tool. Results: From 140 articles returned, 11 systematic reviews, for a total of 21 outcomes (37 RCTs; 3949 participants; almost all using 1500 mg/day), were included. No systematic reviews/ meta-analyses of observational studies were included. Regarding the findings of the metaanalyses, 9/17 outcomes were statistically significant, indicating that GS is more effective than placebo. A high certainty of evidence, as assessed by GRADE, supported the use of GS (versus placebo) in improving the Lequesne Index, joint space width change, joint space width change after 3 years of follow up, joint space narrowing and OA progression. No difference in terms of adverse effects was found between GS and placebo. In systematic reviews, GS was associated with a better glucose profile and a better physical function performance than placebo. Conclusion: GS, when used as a prescription drug (i.e. crystalline glucosamine sulphate) at 1500 mg daily dosage, can positively affect the cartilage structure, reduce pain, improve function and glucose metabolism in people with knee OA, without having a greater incidence of adverse effects than placebo.

Disciplines :

General & internal medicine
Public health, health care sciences & services

Author, co-author :

Veronese, N.

Demurtas, J.

Smith, L.

Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé

Bruyère, Olivier ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé

Beaudart, Charlotte ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé

Honvo, Germain ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé

Maggi, S

Language :

English

Title :

Glucosamine sulphate: an umbrella review of health outcomes

Publication date :

2020

Journal title :

Therapeutic Advances in Musculoskeletal Disease

ISSN :

1759-720X

eISSN :

1759-7218

Publisher :

SAGE Publications, New York, United States - New York

Volume :

Pages :

1-12

Peer reviewed :

Peer Reviewed verified by ORBi

Funders :

on behalf on the European Geriatric Medicine Society Special Interest Groups in Systematic Reviews and Meta-Analyses and Arthritis

Available on ORBi :

since 07 March 2021

Statistics

Number of views

59 (8 by ULiège)

Number of downloads

39 (5 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ 2003; 81: 646–656.
Murray CJ, Vos T, Lozano R, et al Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the global burden of disease study 2010. Lancet 2012; 380: 2197–2223.
Corti MC, Rigon C. Epidemiology of osteoarthritis: prevalence, risk factors and functional impact. Aging Clin Exp Res 2003; 15: 359–363.
Vos T, Flaxman AD, Naghavi M, et al Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the global burden of disease study 2010. Lancet 2012; 380: 2163–2196.
Bruyère O, Altman RD, Reginster J-Y. Efficacy and safety of glucosamine sulfate in the management of osteoarthritis: evidence from real-life setting trials and surveys. Semin Arthritis Rheum 2016; 45: S12–S17.
Reginster J-Y, Veronese N. Highly purified chondroitin sulfate: a literature review on clinical efficacy and pharmacoeconomic aspects in osteoarthritis treatment. Aging Clin Exp Res. Epub ahead of print 7 July 2020. DOI: 10.1007/s40520-020-01643-8.
Bruyère O, Cooper C, Pelletier J-P, et al An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum 2014; 44: 253–263.
Bruyère O, Cooper C, Pelletier J-P, et al A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis – from evidence-based medicine to the real-life setting. Semin Arthritis Rheum 2016; 45: S3–S11.
Bruyère O, Honvo G, Veronese N, et al An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum 2019; 49: 337–350.
De Wan M, Volpi G. Method of preparing mixed glucosamine salts. Google Patents US5847107A, USA, 1998.
Bruyère O, Cooper C, Al-Daghri NM, et al Inappropriate claims from non-equivalent medications in osteoarthritis: a position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Aging Clin Exp Res 2018; 30: 111–117.
Russell AS, Aghazadeh-Habashi A, Jamali F. Active ingredient consistency of commercially available glucosamine sulfate products. J Rheumatol 2002; 29: 2407–2409.
Persiani S, Roda E, Rovati L, et al Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man. Osteoarthritis Cartilage 2005; 13: 1041–1049.
Persiani S, Rotini R, Trisolino G, et al Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose. Osteoarthritis Cartilage 2007; 15: 764–772.
Chiusaroli R, Piepoli T, Zanelli T, et al Experimental pharmacology of glucosamine sulfate. Int J Rheumatol 2011; 2011: 939265.
Reginster JY, Deroisy R, Rovati LC, et al Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001; 357: 251–256.
Pavelká K, Gatterová J, Olejarová M, et al Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002; 162: 2113–2123.
Herrero-Beaumont G, Ivorra JA, Del Carmen Trabado M, et al Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum 2007; 56: 555–567.
Reginster JY. The efficacy of glucosamine sulfate in osteoarthritis: financial and nonfinancial conflict of interest. Arthritis Rheum 2007; 56: 2105–2110.
Towheed TE, Maxwell L, Anastassiades TP, et al Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2009; CD002946.
Eriksen P, Bartels EM, Altman RD, et al Risk of bias and brand explain the observed inconsistency in trials on glucosamine for symptomatic relief of osteoarthritis: a meta-analysis of placebo-controlled trials. Arthritis Care Res (Hoboken) 2014; 66: 1844–1855.
Kucharz EJ, Kovalenko V, Szanto S, et al A review of glucosamine for knee osteoarthritis: why patented crystalline glucosamine sulfate should be differentiated from other glucosamines to maximize clinical outcomes. Curr Med Res Opin 2016; 32: 997–1004.
Bruyère O, Reginster J-Y. Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip osteoarthritis. Drugs Aging 2007; 24: 573–580.
Rozendaal RM, Uitterlinden EJ, van Osch GJ, et al Effect of glucosamine sulphate on joint space narrowing, pain and function in patients with hip osteoarthritis; subgroup analyses of a randomized controlled trial. Osteoarthritis Cartilage 2009; 17: 427–432.
Towheed T. Glucosamine sulphate in osteoarthritis: a systematic review. Arthritis Rheum 1998; 41: S198.
Towheed TE, Maxwell L, Anastassiades TP, et al Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2005; CD002946.
Tenti S, Giordano N, Mondanelli N, et al A retrospective observational study of glucosamine sulfate in addition to conventional therapy in hand osteoarthritis patients compared to conventional treatment alone. Aging Clin Exp Res 2020; 32: 1161–1172.
Moher D, Liberati A, Tetzlaff J, et al Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.
Aromataris E, Fernandez R, Godfrey CM, et al Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach. Int J Evid Based Healthc 2015; 13: 132–140.
Ioannidis JP. Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses. CMAJ 2009; 181: 488–493.
Higgins JP, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions. Chichester: John Wiley & Sons, 2019.
Shea BJ, Reeves BC, Wells G, et al AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ 2017; 358: j4008.
Higgins JP, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A Stat Soc 2009; 172: 137–159.
IntHout J, Ioannidis JPA, Rovers MM, et al Plea for routinely presenting prediction intervals in meta-analysis. BMJ Open 2016; 6: e010247.
Serghiou S, Goodman SN. Random-effects meta-analysis: summarizing evidence with caveats. JAMA 2019; 321: 301–302.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539–1558.
Egger M, Davey Smith G, Schneider M, et al Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629–634.
Carvalho AF, Kohler CA, Brunoni AR, et al Bias in peripheral depression biomarkers. Psychother Psychosom 2016; 85: 81–90.
Guyatt GH, Oxman AD, Vist GE, et al GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924.
Hsu C-H, Hsu N-C, Shih C-L, et al Medication-taking habit and outcome of glucosamine sulfate for osteoarthritis patients influenced by national health insurance regulations in Taiwan. J Clin Med 2019; 8: 1734.
Richy F, Bruyère O, Ethgen O, et al Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 2003; 163: 1514–1522.
Lee YH, Woo JH, Choi SJ, et al Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta-analysis. Rheumatol Int 2010; 30: 357–363.
Dostrovsky NR, Towheed TE, Hudson RW, et al The effect of glucosamine on glucose metabolism in humans: a systematic review of the literature. Osteoarthritis Cartilage 2011; 19: 375–380.
Sodha R, Sivanadarajah N, Alam M. The use of glucosamine for chronic low back pain: a systematic review of randomised control trials. BMJ Open 2013; 3: e001167.
Gallagher B, Tjoumakaris FP, Harwood MI, et al Chondroprotection and the prevention of osteoarthritis progression of the knee: a systematic review of treatment agents. Am J Sports Med 2015; 43: 734–744.
Gregori D, Giacovelli G, Minto C, et al Association of pharmacological treatments with long-term pain control in patients with knee osteoarthritis: a systematic review and meta-analysis. JAMA 2018; 320: 2564–2579.
Knapik JJ, Pope R, Hoedebecke SS, et al Effects of oral glucosamine sulfate on osteoarthritis-related pain and joint-space changes: systematic review and meta-analysis. J Spec Oper Med 2018; 18: 139–147.
Melo G, Casett E, Stuginski-Barbosa J, et al Effects of glucosamine supplements on painful temporomandibular joint osteoarthritis: a systematic review. J Oral Rehabil 2018; 45: 414–422.
Simental-Mendia M, Sanchez-Garcia A, Vilchez-Cavazos F, et al Effect of glucosamine and chondroitin sulfate in symptomatic knee osteoarthritis: a systematic review and meta-analysis of randomized placebo-controlled trials. Rheumatol Int 2018; 38: 1413–1428.
Honvo G, Reginster JY, Rabenda V, et al Safety of symptomatic slow-acting drugs for osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs Aging 2019; 36: 65–99.
Gallagher B, Tjoumakaris FP, Harwood MI, et al. Chondroprotection and the prevention of osteoarthritis progression of the knee: a systematic review of treatment agents. Am J Sports Med. 2015; 43: 734–744.
Lee YH, Woo JH, Choi SJ, Ji JD, et al. Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta-analysis. Rheumatol Int. 2010; 30:357–363.
Bruyère O, Reginster J-Y, Honvo G, et al Cost-effectiveness evaluation of glucosamine for osteoarthritis based on simulation of individual patient data obtained from aggregated data in published studies. Aging Clin Exp Res 2019; 31: 881–887.
Hopman W, Towheed T, Gao Y, et al Prevalence of and factors associated with glucosamine use in Canada. Osteoarthritis Cartilage 2006; 14: 1288–1293.
Galvin R, Cousins G, Boland F, et al Prescribing patterns of glucosamine in an older population: a national cohort study. BMC Complement Altern Med 2013; 13: 316.
Dechant JE, Baxter GM, Frisbie DD, et al Effects of glucosamine hydrochloride and chondroitin sulphate, alone and in combination, on normal and interleukin-1 conditioned equine articular cartilage explant metabolism. Equine Vet J 2005; 37: 227–231.
Chiusaroli R, Visentini M, Galimberti C, et al Targeting of ADAMTS5’s ancillary domain with the recombinant mAb CRB0017 ameliorates disease progression in a spontaneous murine model of osteoarthritis. Osteoarthritis Cartilage 2013; 21: 1807–1810.
Lequesne MG, Mery C, Samson M, et al Indexes of severity for osteoarthritis of the hip and knee. Validation–value in comparison with other assessment tests. Scand J Rheumatol Suppl 1987; 65: 85–89.
Cohen J. Statistical power analysis for the behavioral sciences. New York, NY: Academic Press, 2013.
Towheed TE, Maxwell L, Judd MG, et al Acetaminophen for osteoarthritis. Cochrane Database Syst Rev 2006; CD004257.
Veronese N, Cooper C, Reginster J-Y, et al Type 2 diabetes mellitus and osteoarthritis. Semin Arthritis Rheum 2019; 49: 9–19.
Gommans YMM, Runhaar J, Jacobs ML, et al The effect of prolonged glucosamine usage on HbA1c levels and new-onset diabetes mellitus in overweight and obese middle-aged women. Am J Med 2017; 130: 731–737.e736.
Ma H, Li X, Zhou T, et al Glucosamine use, inflammation, and genetic susceptibility, and incidence of type 2 diabetes: a prospective study in UK Biobank. Diabetes Care 2020; 43: 719–725.
Ma H, Li X, Sun D, et al Association of habitual glucosamine use with risk of cardiovascular disease: prospective study in UK Biobank. BMJ 2019; 365: l1628.
Li Z-H, Gao X, Chung VC, et al Associations of regular glucosamine use with all-cause and cause-specific mortality: a large prospective cohort study. Ann Rheum Dis 2020; 79: 829–836.
Largo R, Alvarez-Soria MA, Díez-Ortego I, et al Glucosamine inhibits IL-1β-induced NFκB activation in human osteoarthritic chondrocytes. Osteoarthritis Cartilage 2003; 11: 290–298.
Herrero-Beaumont G, Largo R. Glucosamine and O-GlcNAcylation: a novel immunometabolic therapeutic target for OA and chronic, low-grade systemic inflammation? London: BMJ Publishing Group Ltd, 2020.
Tsalamandris S, Antonopoulos AS, Oikonomou E, et al The role of inflammation in diabetes: current concepts and future perspectives. Eur Cardiol 2019; 14: 50–59.
Charlesworth J, Fitzpatrick J, Perera NKP, et al Osteoarthritis – a systematic review of long-term safety implications for osteoarthritis of the knee. BMC Musculoskelet Disord 2019; 20: 151.
Ioannidis JP. The mass production of redundant, misleading, and conflicted systematic reviews and meta-analyses. Milbank Q 2016; 94: 485–514.
Bruyère O, Pavelka K, Rovati LC, et al Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials. Osteoarthritis Cartilage 2008; 16: 254–260.
Scholtissen S, Bruyère O, Neuprez A, et al Glucosamine sulphate in the treatment of knee osteoarthritis: cost-effectiveness comparison with paracetamol. Int J Clin Pract 2010; 64: 756–762.